Acute Efficacy and Safety of Escitalopram Versus Desvenlafaxine and Vortioxetine in the Treatment of Depression With Cognitive Complaint: A Rater-Blinded Randomized Comparative Study
CONCLUSION: In acute antidepressant treatment for MDD with CC, escitalopram, vortioxetine, and desvenlafaxine presented similar efficacy in relief of depressive symptoms; however, desvenlafaxine was associated with a superior treatment. Further studies are needed to confirm these results by investigating the therapeutic efficacy and safety profile of long-term antidepressant treatment of MDD with CC (Clinical Trial Registry, http://cris.nih.go.kr/cris/en/: KCT0002173).PMID:35500900 | DOI:10.30773/pi.2021.0368 (Source: Psychiatry Investigation)
Source: Psychiatry Investigation - May 2, 2022 Category: Psychiatry Authors: Seung-Hoon Lee Sang Won Jeon Cheolmin Shin Chi-Un Pae Ashwin A Patkar Prakash S Masand Hyonggin An Changsu Han Source Type: research
Depression and Long-Term Prescription Opioid Use and Opioid Use Disorder: Implications for Pain Management in Cancer
Opinion statementPreventing depression in cancer patients on long-term opioid therapy should begin with depression screening before opioid initiation and repeated screening during treatment. In weighing the high morbidity of depression and opioid use disorder in patients with chronic cancer pain against a dearth of evidence-based therapies studied in this population, patients and clinicians are left to choose among imperfect but necessary treatment options. When possible, we advise engaging psychiatric and pain/palliative specialists through collaborative care models and recommending mindfulness and psychotherapy to all pa...
Source: Current Treatment Options in Oncology - March 7, 2022 Category: Cancer & Oncology Source Type: research
Selective publication of antidepressant trials and its influence on apparent efficacy: Updated comparisons and meta-analyses of newer versus older trials
ConclusionsReporting bias persists but appears to have diminished for newer, compared to older, antidepressants. Continued efforts are needed to further improve transparency in the scientific literature. (Source: PLoS Medicine)
Source: PLoS Medicine - January 19, 2022 Category: Internal Medicine Authors: Erick H. Turner Source Type: research
Involvement of oxidative pathways and BDNF in the antidepressant effect of carvedilol in a depression model induced by chronic unpredictable stress
ConclusionsCARV presents antidepressant-like effects comparable to those observed with DVS. In addition, it has an antioxidant effect and is capable of increasing BDNF brain concentrations. Further studies are needed to elucidate the mechanisms involved in the antidepressant effect of CARV. (Source: Psychopharmacology)
Source: Psychopharmacology - January 13, 2022 Category: Psychiatry Source Type: research
Adherence to Desvenlafaxine Versus Usual Care and Its Impact on Health Outcomes: A Comparative Real-world Clinical Study
ConclusionsDesvenlafaxine is significantly associated with a higher adherence rate at 12 months compared to usual care based on SSRI or other SNRI. This suggests that desvenlafaxine could improve disease management having a positive impact on disease-associated costs. (Source: Clinical Drug Investigation)
Source: Clinical Drug Investigation - November 6, 2021 Category: Drugs & Pharmacology Source Type: research
Pharmacological Characterization of Toludesvenlafaxine as a Triple Reuptake Inhibitor
This study characterized the in vitro triple reuptake inhibition activity, antidepressant-like activity in animals, and pharmacokinetic profiles in rats of toludesvenlafaxine. Binding affinity was determined using human serotonin transporter (SERT) protein, norepinephrine transporter (NET) protein and dopamine transporter (DAT) protein, and the reuptake inhibition was determined using Chinese hamster ovary cells expressing human SERT, NET and DAT. The antidepressant-like activity was examined in rat chronic unpredictable mild stress model and olfactory bulbectomized model. In rats, the tissue distribution and pharmacokinet...
Source: Frontiers in Pharmacology - September 14, 2021 Category: Drugs & Pharmacology Source Type: research
Trajectories of Function and Symptom Change in Desvenlafaxine Clinical Trials: Toward Personalized Treatment for Depression
Conclusions
Distinct trajectories of change based on symptoms and functioning were identified among patients with MDD receiving desvenlafaxine and among patients with MDD receiving placebo. Differentiating subpopulations of patients has the potential to provide a more personalized treatment of patients with MDD.
ClinicalTrials.govIdentifiers: NCT00072774; NCT00277823; NCT00300378; NCT00384033; NCT00798707; NCT00863798; NCT01121484; NCT00824291; NCT01432457. (Source: Journal of Clinical Psychopharmacology)
Source: Journal of Clinical Psychopharmacology - September 1, 2021 Category: Psychiatry Tags: Brief Reports Source Type: research
